BioCentury
ARTICLE | Management Tracks

New COO, CBO at Nutcracker

Plus Guindo rejoins Merck to lead marketing of human health business, and updates from Arcellx, Angiex, Congenica and more

June 22, 2022 10:53 PM UTC

RNA therapies company Nutcracker Therapeutics Inc. hired John Stubenrauch as COO, Geoff Nosrati as CBO and Ian Wiener as EVP and general counsel. Stubenrauch was VP of biologics commercial operations at Gilead Sciences Inc. (NASDAQ:GILD), Nosrati was CBO at ImmunoSCAPE Ptd. Ltd., and Wiener was a partner at Irell & Manella, a law firm.

Chirfi Guindo will rejoin Merck & Co. Inc. (NYSE:MRK) on July 1 as chief marketing officer at Merck Human Health. Guindo joins from Biogen Inc. (NASDAQ:BIIB), where he was most recently EVP, head of global product strategy and commercialization. Before Biogen, Guindo held various roles at Merck for 26 years, including as managing director of the company in Canada, Netherlands and South Africa and as general manager and head of its global HIV franchise...